| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10806733 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(8 years from now) | |
| US10034879 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(8 years from now) | |
| US9018210 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Nov, 2033
(9 years from now) | |
| US9447071 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10017491 | GLOBAL BLOOD THERAPS | Compounds and uses thereof for the modulation of hemoglobin |
Dec, 2032
(8 years from now) | |
| US9248199 | GLOBAL BLOOD THERAPS | 1:1 adducts of sickle hemoglobin |
Jan, 2034
(9 years from now) | |
| US11452720 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(10 years from now) | |
| US10722502 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(10 years from now) | |
| US11020382 | GLOBAL BLOOD THERAPS | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Dec, 2036
(12 years from now) | |
| US10493035 | GLOBAL BLOOD THERAPS | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Oct, 2037
(13 years from now) | |
Oxbryta is owned by Global Blood Theraps.
Oxbryta contains Voxelotor.
Oxbryta has a total of 10 drug patents out of which 0 drug patents have expired.
Oxbryta was authorised for market use on 17 December, 2021.
Oxbryta is available in tablet;oral dosage forms.
Oxbryta can be used as treatment of sickle cell disease by administering voxelotor, as recited in claim 2, increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily, treating sickle cell disease by administering voxelotor and another active agent.
Drug patent challenges can be filed against Oxbryta from 26 November, 2023.
The generics of Oxbryta are possible to be released after 12 October, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
| Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 17 December, 2021
Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by administering voxelotor and another active agent; Increasing hemoglobin to treat sic...
Dosage: TABLET;ORAL
OXBRYTA family patents
